Investors

Press Releases

All Releases

View Summary New Film Documents Heart Felt Stories of People Living with High LDL Cholesterol
Jun 30, 2015
PDF 14.3 KB Add to Briefcase
View Summary Regeneron Rapid Response Platform for Emerging Infectious Diseases Described in Proceedings of the National Academy of Sciences Publication
Jun 29, 2015
PDF 13.0 KB Add to Briefcase
View Summary EYLEA® (aflibercept) Injection Receives Approval in Japan for the Treatment of Retinal Vein Occlusion
Jun 26, 2015
PDF 16.5 KB Add to Briefcase
View Summary Regeneron Announces 2015 Winners of the Regeneron Prize for Creative Innovation
Jun 25, 2015
PDF 8.5 KB Add to Briefcase
View Summary FDA Advisory Committee Recommends Approval of Regeneron and Sanofi's Praluent® (alirocumab) Injection for Patients with Hypercholesterolemia
Jun 9, 2015
PDF 17.9 KB Add to Briefcase
View Summary Trading in Regeneron Common Stock Halted
Jun 9, 2015
PDF 10.9 KB Add to Briefcase
View Summary Regeneron and Sanofi Announce Positive Topline Results from Phase 3 Studies with Sarilumab in Patients with Rheumatoid Arthritis
May 21, 2015
PDF 16.7 KB Add to Briefcase
View Summary Regeneron and Sanofi Announce Positive Pivotal Phase 2b Dupilumab Data in Asthma Presented at the American Thoracic Society 2015 International Conference
May 18, 2015
PDF 20.3 KB Add to Briefcase
View Summary Regeneron Reports First Quarter 2015 Financial and Operating Results
May 7, 2015
PDF 38.1 KB Add to Briefcase
View Summary Regeneron Announces Upcoming 2015 Investor Conference Presentations
Apr 29, 2015
PDF 8.0 KB Add to Briefcase
View Summary Regeneron to Report First Quarter 2015 Financial and Operating Results and Host Conference Call and Webcast on May 7, 2015
Apr 10, 2015
PDF 8.2 KB Add to Briefcase
View Summary EYLEA® (aflibercept) Injection Receives FDA Approval for the Treatment of Diabetic Retinopathy in Patients with Diabetic Macular Edema (DME)
Mar 25, 2015
PDF 19.3 KB Add to Briefcase
View Summary Regeneron and Sanofi Announce 18-Month Results of ODYSSEY LONG TERM Trial with Praluent™ (alirocumab) Published in The New England Journal of Medicine
Mar 15, 2015
PDF 20.6 KB Add to Briefcase
View Summary EYLEA® (aflibercept) Injection Receives EU Approval for the Treatment of Visual Impairment Due to Macular Edema Secondary to Retinal Vein Occlusion
Feb 26, 2015
PDF 16.2 KB Add to Briefcase
View Summary NIH-Sponsored Comparative Effectiveness Trial in Diabetic Macular Edema Shows EYLEA® (aflibercept) Injection Demonstrated Significantly Greater Gains in Visual Acuity than Both Bevacizumab and Ranibizumab
Feb 18, 2015
PDF 20.6 KB Add to Briefcase
View Summary New Results from Cholesterol Counts Show Most Americans Polled Do Not Know Their Bad Cholesterol (LDL-C) Levels
Feb 18, 2015
PDF 22.5 KB Add to Briefcase
View Summary Regeneron Announces Upcoming 2015 Investor Conference Presentations
Feb 13, 2015
PDF 7.8 KB Add to Briefcase
View Summary Regeneron Reports Fourth Quarter and Full Year 2014 Financial and Operating Results
Feb 10, 2015
PDF 41.2 KB Add to Briefcase
View Summary Regeneron and Sanofi Announce Praluent™ (alirocumab) Biologics License Application has Been Accepted for Priority Review by US FDA
Jan 26, 2015
PDF 15.8 KB Add to Briefcase
View Summary EYLEA® (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment Due to Macular Edema Secondary to Central or Branch Retinal Vein Occlusion in the European Union
Jan 23, 2015
PDF 16.0 KB Add to Briefcase
Showing 1-20 of 276 Page: 1 2 3 4 5 ... 14  Next 20
Add to Briefcase = add release to Briefcase


Close
Form content here please :)